Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancer

21 Dec 2022

Abstract excerpt

Acquired resistance is a major obstacle to the therapeutic efficacy of osimertinib in non-small-cell lung cancer (NSCLC). Current knowledge about the role of long non-coding RNAs (lncRNAs) in this phenomenon is insufficient. In this study, we screened the differentially expressed lncRNAs between osimertinib-sensitive and -resistant NSCLC cell lines, and determined that lnc-TMEM132D-AS1 was significantly...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Cancer-related molecular mechanisms research
Share to Cholangiocarcinoma and Gallbladder Cancer Studies
Share to Lung Cancer Treatments and Mutations

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Identifiers

PMID: 36651104
DOI: 10.1039/d2mo00261b

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Lnc-TMEM132D-AS1 as a potential therapeutic target for acquired resistance to osimertinib in non-small-cell lung cancerPMID 36651104Read ↗

Lnc-TMEM132D-AS1 Confers Acquired Resistance to Osimertinib in Non-Small-Cell Lung CancerSemantic proximity Read ↗

Characterization of circRNAs in established osimertinib‑resistant non‑small cell lung cancer cell linesSemantic proximity Read ↗

Exosomal microRNAs as potential biomarkers for osimertinib resistance of non-small cell lung cancer patientsSemantic proximity Read ↗

Bulk RNA analysis identified the characteristics and immunoinvasive patterns of osimertinib resistance in patients with non-small cell lung cancerSemantic proximity Read ↗

Resistance mechanisms to osimertinib and emerging therapeutic strategies in nonsmall cell lung cancer.Semantic proximity Read ↗

ID1 mediates resistance to osimertinib in EGFR T790M-positive non-small cell lung cancer through epithelial-mesenchymal transition.Semantic proximity Read ↗

Comprehensive review of LncRNA-mediated therapeutic resistance in non-small cell lung cancerSemantic proximity Read ↗

A cohort-based multi-omics identifies nuclear translocation of eIF5B /PD-L1/CD44 complex as the target to overcome Osimertinib resistance of ARID1A-deficient lung adenocarcinomaSemantic proximity Read ↗

METTL14-Mediated Bim mRNA m6A Modification Augments Osimertinib Sensitivity in EGFR-Mutant NSCLC Cells.Semantic proximity Read ↗

MicroRNA-130a-3p regulates osimertinib resistance by targeting runt-related transcription factor 3 in lung adenocarcinomaSemantic proximity Read ↗

Mechanisms analysis for Formononetin counteracted-Osimertinib resistance in Non-small-cell lung cancer cells: from the insight into the gene transcriptional levelSemantic proximity Read ↗

Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.